Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

CORRECTED-British healthcare firm Bupa extends 800 mln pound credit line

Published 06/08/2015, 05:57 pm
© Reuters.  CORRECTED-British healthcare firm Bupa extends 800 mln pound credit line

(Corrects to read private healthcare, not health insurance, paragraph 13)

By Carolyn Cohn

LONDON, Aug 6 (Reuters) - British private healthcare group Bupa BUPAI.UL has extended an 800 million pound ($1.25 billion) syndicated credit facility by three years to 2020 at least to strengthen its capital buffers, its chief executive said.

European Union Solvency II regulations for insurers come into force in January 2016, and are expected to require firms to set aside more capital in the event of shocks to their business.

Bupa gets around 70 percent of its revenue from health insurance but also operates hospitals, care homes and medical clinics in many of its businesses around the world.

"We need headroom in terms of solvency capital," Stuart Fletcher told Reuters in a telephone interview.

Fletcher said the extension had been negotiated at better terms than the previous facility. It has been extended to 2020 from the previous 2017 maturity date, with an option to extend again, to 2022.

The company issued a 350 million pound seven-year bond last year with a coupon of 3.375 percent, currently trading at a yield of 3.0 percent GB107530975= .

Fletcher said there were no plans for more debt issuance in the next 12 months.

Bupa posted first-half results on Thursday showing underlying pre-tax profit rose 2 percent to 253 million pounds from a year earlier, on a constant exchange rate basis.

But profits dropped in the firm's British and Australian and New Zealand units, key areas of its business.

In Britain, Fletcher said that high inflation in medical costs was affecting profits.

Bupa, set up in 1947 just ahead of the formation of Britain's national health service to provide an alternative health provision, ploughs all its profits back into the business.

The firm has been expanding in emerging markets such as Chile in recent years.

It has made several acquisitions in Poland this year, where it said it was the market leader in private healthcare. It bought Warsaw-based oncology provider Magodent last month for an undisclosed sum.

Fletcher said the group had no plans for major acquisitions this year, but would look at "fill-in" deals, for instance in Australia.

Bupa would come in at around 50-60th position in the FTSE-100 if it were a listed company. It has 2 billion pounds in outstanding debt.

($1 = 0.6408 pounds) (Editing by Susan Fenton)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.